Bio-Techne Corporation (TECH)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Life Science Toolssrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 4.74% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- 1 Unpopular Stock That Should Get More Attention and 2 We Question
- Bio-Techne opens GMP small molecule facility in Bristol, UK
- Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development
- 2 Cash-Producing Stocks Worth Investigating and 1 We Brush Off
- Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
- Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
- Bio Techne (TECH) And The Valuation Case Behind Its Recent Rebound
- Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Bio-Techne Corporation.
Full TECH Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.